21 April 2017 - Report expected to include review of Ingrezza, recently approved, and Austedo, currently under FDA review; ICER's open input period now open until 12 May 2017.

The Institute for Clinical and Economic Review (ICER) will develop a report assessing the comparative clinical effectiveness and value of drugs to treat tardive dyskinesia, a condition characterised by involuntary movements that is associated, in many cases, with long-term use of antipsychotic medications. 

ICER's report is expected to review evidence on valbenazine (Ingrezza, Neurocrine Biosciences), the first drug approved for tardive dyskinesia, along with deutetrabenazine (Austedo, Teva Pharmaceuticals), a drug currently approved for use in Huntington's disease and under review by the FDA for tardive dyskinesia. An approval decision for deutetrabenazine in this indication is expected by 30 August 2017. 

The report is also likely to include tetrabenazine (Xenazine, Lundbeck), a drug approved for treatment of involuntary movements associated with Huntington's disease, but also used in patients with tardive dyskinesia. This preliminary list of drugs is tentative and subject to change as the scope of the review develops.

Read ICER press release